Login
Companies $SPRO
$0.93 -$0.02 (1.73%) After hours
Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.

sperotherapeutics.com

What Do They Do?

Develops an oral antibiotic for adults with complicated urinary tract infections and pursues treatments for rare diseases and diseases with high unmet need.

How Do They Make Money?

Drug partners pay upfront and when development or sales milestones are reached for licensed drug rights; Spero may also receive royalties tied to licensed-product sales.

revenue
SegmentShareRevenue
Grant Revenue
11%
Collaboration revenue - related party
Licensed

70%
Collaboration revenue
19%

Who Are Their Customers?

Drug companies license rights to develop and commercialize Spero’s drug candidates; GSK holds rights for tebipenem in most territories, while Meiji retains rights in certain Asian territories.

Do Revenues Turn Into Profits?

Yes. It kept 13 cents of every revenue dollar as net income in FY2025.

Operating income, FY2025
9% of revenue
▲ Turned profitable vs FY2024 (−$73.4M, −153%)
Net income, FY2025
13% of revenue
▲ Turned profitable vs FY2024 (−$68.6M, −143%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $5.4M in Q3 FY2025
Net income
▼ −500% (Loss)
vs −$7.4M in Q3 FY2025
  • Jul 8, 2026 Licensed SP001 antibody rights from Innovent Spero obtained rights outside Greater China to develop, manufacture and commercialize SP001, an antibody targeting CD40L.
  • Jun 17, 2026 FDA approved Utebzi for adults with complicated urinary tract infections The approval covers adults with cUTIs, including pyelonephritis, caused by certain susceptible pathogens who have limited or no alternative oral treatment options.

Growing. Revenue grew 3.7x in 4 years, from $18.3M in FY2021 to $66.8M in FY2025, about 38% a year.

Portfolio focus The older report presents an oral treatment for NTM lung disease as the lead program and describes other infection candidates. The latest report says earlier-stage programs have ended and focuses on supporting GSK’s FDA process for tebipenem while exploring other clinical-stage candidates.

Revenue over time
Grant Revenue Collaboration revenue - related party Collaboration revenue
$200M$100M$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support